A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.
An E1B 55 kDa gene-deleted adenovirus, Onyx-015, which reportedly selectively replicates in and lyses p53-deficient cells, was administered by a single intratumoral injection to a total of 22 patients with recurrent head and neck cancer. The objectives of this Phase I study were to determine the safety, feasibility, and efficacy of this therapy and determine any correlation to p53 status. Six cohorts were investigated with a dose escalation from 10(7)-10(11) plaque-forming units. Toxicity was assessed using NCIC criteria. Tumor response was assessed by clinical and radiological measurement. Blood samples were taken to detect adenovirus DNA and neutralizing antibody to adenovirus. Tumor biopsies were taken to detect adenovirus by in situ hybridization. Treatment was well tolerated, with the main toxicity being grade 1/2 flu-like symptoms. Dose-limiting toxicity was not reached at the highest dose of 10(11) plaque-forming units. Twenty-one of the 22 patients treated showed an increase in neutralizing antibody to adenovirus. In situ hybridization showed viral replication in 4 of 22 patients treated, all of whom had mutant p53 tumors. Using conventional response criteria, no objective responses were observed. However, magnetic resonance imaging scans were suggestive of tumor necrosis at the site of viral injection in five patients, three of whom were classified using nonconventional criteria as partial responders, and two of whom were classified using nonconventional criteria as minor responders. Of these five cases, four had mutant p53 tumors. The response duration for the three partial responders was 4, 8, and 12 weeks. An additional eight patients had stable disease in the injected tumors lasting from 4-8 weeks. These preliminary results show that intratumoral administration of Onyx-015 is feasible, well tolerated, and associated with biological activity. Further investigation of Onyx-015, particularly with a more frequent injection protocol and in combination with systemic chemotherapy, is warranted.
Ganly
I
I
Cancer Research Campaign Department of Medical Oncology, CRC Beatson Laboratories, Glasgow, United Kingdom. ig8j@udcf.gla.ac.uk
Kirn
D
D
Eckhardt
G
G
Rodriguez
G I
GI
Soutar
D S
DS
Otto
R
R
Robertson
A G
AG
Park
O
O
Gulley
M L
ML
Heise
C
C
Von Hoff
D D
DD
Kaye
S B
SB
Eckhardt
S G
SG
D017501:Adenovirus E1B Proteins / Q000235:genetics*; D000260:Adenoviruses, Human / Q000235:genetics*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000097:blood; D000917:Antibody Formation; D003588:Cytopathogenic Effect, Viral; D004279:DNA, Viral / Q000008:administration & dosage* / Q000009:adverse effects / Q000235:genetics; D003673:Defective Viruses / Q000235:genetics; D005260:Female; D005334:Fever / Q000209:etiology; D006258:Head and Neck Neoplasms / Q000473:pathology / Q000628:therapy* / Q000821:virology; D006801:Humans; D017403:In Situ Hybridization; D015552:Injections, Intralesional; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009325:Nausea / Q000209:etiology; D009364:Neoplasm Recurrence, Local; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000235:genetics
D017501:Adenovirus E1B Proteins; D000914:Antibodies, Viral; D004279:DNA, Viral; D016159:Tumor Suppressor Protein p53